Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 17

Pertuzumab
•
A mechanism of action designed to bind to the
HER dimerisation domain
•
By targeting HER2, the preferred pairing partner for
HER1, HER3 and HER4, pertuzumab may
inhibit
multiple HER signaling pathways
AKT
PDK1
cell cycle
control
↓
apoptosis
survival
Cyclin D1
p27
BAD
GSK3
NF
B
mTOR
P P P P P
proliferation
angiogenesis
P13K
HER3
HER2
Trastuzumab
Pertuzumab: A HER dimerisation
inhibitor
Pertuzumab
1...,7,8,9,10,11,12,13,14,15,16 18,19,20,21,22,23,24,25,26,27,...47
Powered by FlippingBook